News

GLP-1 news ledger: 17 developments to November 20, 2026

Released: · Last reviewed: · By Dr. Parmis

Each entry is one dated development with its primary source, a short summary and what it means if you pay cash. Below the ledger are our longer explainers on the 503B proposal, counterfeit Ozempic and FDA enforcement.

News ledger, newest first

November 20 re-read: Found lowers its cash prices, Noom and Zappy print compounded prices, Henry Meds drops its tirzepatide price

· confirmed (first-party pages) · effective

In the November 20, 2026 re-read of the programs this site reviews, Found cut compounded tirzepatide to $339 a cycle month to month and $199 on a 12-month term (from $359 and $239 on October 15), Noom printed $299 a month for tirzepatide and $249 for semaglutide after a lower first month, Zappy Health printed $349 and $249 month to month, and Henry Meds no longer printed an injectable tirzepatide price.

What it means if you pay cash: Programs reprice between reads; compare the plan length and the read date, not just the headline figure.

What changed on this site: Competitor prices on the price page, provider pages and the re-score now use the November 20 reads.

Source: Found: compounded tirzepatide store page · Last verified November 20, 2026

503B bulks-list exclusion of tirzepatide and semaglutide: still proposed

· confirmed (no final notice found) · proposed

Federal Register searches on November 20, 2026 found no final notice on FDA's April 30, 2026 proposal not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list; comments closed July 30, 2026.

What it means if you pay cash: No material verified change: 503A patient-specific compounding, the route telehealth programs use, is unaffected for now.

What changed on this site: No material verified change.

Source: Federal Register, 91 FR 23431 (May 1, 2026) · Last verified November 20, 2026

FDA adds an optic-nerve (NAION) warning to every approved GLP-1 label

· confirmed (FDA) · effective (label updates to follow)

FDA's November 9, 2026 Drug Safety Communication requires a potential increased risk of non-arteritic anterior ischemic optic neuropathy in the Warnings and Precautions of all approved GLP-1 receptor agonists, including Zepbound, Mounjaro, Wegovy, Ozempic and Foundayo. In FDA's meta-analysis of 126 trials the rate was 6.4 versus 3.8 cases per 100,000 person-years. FDA does not mention compounded products.

What it means if you pay cash: Sudden, painless vision loss in one eye is a reason to call a clinician the same day, whichever GLP-1 you take.

What changed on this site: The safety notes on the medication pages cite the new warning.

Source: FDA Drug Safety Communication, November 9, 2026 · Last verified November 20, 2026

Hims & Hers 10-Q: FTC case hearing set for January 14, 2027; compounded GLP-1s "on a limited scale"

· confirmed (SEC filing) · pending (case unresolved)

Hims & Hers' third-quarter 10-Q says it moved to dismiss the July 29, 2026 FTC, Utah and Los Angeles County complaint on October 22, with a hearing set for January 14, 2027, and had accrued about $60 million for the matter. It says it now offers compounded GLP-1s only on a limited scale through 503A pharmacies.

What it means if you pay cash: The FTC case concerns subscription and cancellation practices and is unresolved; read Hims' cancellation terms before you subscribe.

What changed on this site: Hims & Hers stays "not scored" here because its pages were unreachable in the November 20 re-read.

Source: Hims & Hers Health, Form 10-Q for the quarter ended September 30, 2026 (SEC) · Last verified November 20, 2026

NexLife prices its microdose plans the same as its standard plans

· confirmed (first-party page)

NexLife's microdose tirzepatide and microdose semaglutide program pages now show the same four prices as its standard plans: $129, $125, $119 and $115 a month for tirzepatide and $109, $105, $99 and $95 for semaglutide (month to month, 3, 6 and 12 months). This site had recorded microdose tirzepatide at $189 to $147 and microdose semaglutide at $129 to $110 in July 2026.

What it means if you pay cash: A lower starting dose no longer changes the monthly price at NexLife; compare plan lengths, not formulations.

Source: NexLife microdose tirzepatide program · Last verified November 20, 2026

Lilly and Hims & Hers: Zepbound and Foundayo at Lilly self-pay prices on the Hims platform

· confirmed (company release) · announced

Lilly and Hims & Hers announced that eligible Hims patients can buy Zepbound from $299 a month and Foundayo from $149 at Lilly's self-pay prices without leaving the platform. The release does not state a Hims membership fee, a start date or the dispensing pharmacy.

What it means if you pay cash: Add any platform membership to the brand price before you compare it with an all-in compounded price.

What changed on this site: No score change: Hims & Hers was not scored in this re-read.

Source: Lilly and Hims & Hers joint release (PR Newswire), November 6, 2026 · Last verified November 20, 2026

NexLife lowers its standard compounded tirzepatide and semaglutide prices

· confirmed (first-party page)

From November 6, 2026 NexLife charges $129 a month for compounded tirzepatide month to month and $125, $119 and $115 on 3-, 6- and 12-month plans; semaglutide is $109, $105, $99 and $95. When read on October 15, 2026 the same plans cost $169 to $139 (tirzepatide) and $139 to $119 (semaglutide). The plans keep one price at every dose and no membership fee.

What it means if you pay cash: A 12-month tirzepatide plan now totals $1,380 and a 12-month semaglutide plan $1,140 at NexLife's listed rates.

Source: NexLife tirzepatide plans · Last verified November 20, 2026

FDA warning letter 737905 to telehealth seller RonanRx over "FDA-approved compounded" and "American made" claims

· confirmed (FDA) · open (no close-out)

FDA's October 30, 2026 letter (posted November 3) says RonanRx described compounded semaglutide and tirzepatide as FDA-approved and as American made, and pictured labels suggesting it compounded the drugs. FDA says its records list no US-registered maker of semaglutide or tirzepatide active ingredient for compounding.

What it means if you pay cash: "FDA-approved compounded" is a contradiction; a program should say compounded drugs are not FDA-approved.

What changed on this site: Sub-check RD1 of the re-score checks for that statement on every program.

Source: FDA warning letter 737905 to RonanRx · Last verified November 20, 2026

Four Class II recalls of compounded GLP-1s from pharmacies in South Carolina, North Carolina and Texas

· confirmed (FDA enforcement reports) · ongoing

FDA enforcement reports of October 14 and 21 and November 11, 2026 list voluntary Class II recalls of compounded semaglutide or tirzepatide products from Carolina Infusion, Apothecary Pharma and Houston Rx (lack of assurance of sterility) and Victory Medical Center Pharmacy (lack of processing controls). None of the four is named as a pharmacy by any program this site reviews.

What it means if you pay cash: The pharmacy name on your vial label is what to check against a recall list.

What changed on this site: The pharmacy board and the new pharmacy article map named pharmacies to FDA records.

Source: openFDA drug enforcement reports (tirzepatide, September-December 2026) · Last verified November 20, 2026

Mochi Health's per-dose compounded pricing reaches the press

· confirmed (first-party page)

Mochi's own post says compounded semaglutide now costs $60 to $99 a month and tirzepatide $90 to $199 by dose, with membership billed separately; a News Beep article on October 13, 2026 covered the pricing. Mochi's FAQ, read November 10, 2026, lists membership at $79 for one month, $207 for 3, $354 for 6 and $588 for 12.

What it means if you pay cash: Mochi's entry-dose price plus a one-month membership is $139 for semaglutide and $169 for tirzepatide; higher doses cost more.

Source: Mochi Health: New per-dose pricing · Last verified November 20, 2026

Walmart to cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027

· reported (news report, not a Walmart plan document)

CNBC reported on October 13, 2026 that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after prior authorization. The report says Walmart still does not cover GLP-1s for weight loss.

What it means if you pay cash: Employees who want a GLP-1 for weight loss stay in the cash-pay market.

Source: CNBC, October 13, 2026 · Last verified November 20, 2026

FDA's GLP-1 import "green list" (Import Alert 66-80) is updated

· confirmed (agency page)

The current version of FDA Import Alert 66-80, published October 9, 2026, lets FDA detain GLP-1 active ingredients (APIs) offered for import without physical examination unless the manufacturer and drug are on its "green list"; firm names on the public page are redacted. Our count of the page found 21 green-list entries, 12 of them in China and 3 in India, with semaglutide in 10 entries and tirzepatide in 9.

What it means if you pay cash: None of the compounded programs we read names the maker or country of its active ingredient, so a patient cannot check a supply against the list.

Source: FDA Import Alert 66-80 · Last verified November 20, 2026

FDA updates its page on unapproved GLP-1 drugs

· confirmed (agency page)

FDA's "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page, current as of October 1, 2026, lists telehealth red flags, a 28-day discard rule for compounded multi-dose GLP-1 vials, a warning against semaglutide salt forms, and a statement that retatrutide and cagrilintide cannot be used in compounding under federal law. It reports 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026.

What it means if you pay cash: Ask your program which form of the drug your pharmacy uses and how long a multi-dose vial may be used.

Source: FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · Last verified November 20, 2026

Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss

· confirmed

From October 1, 2026 Rhode Island Medicaid no longer covers Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, per a Tufts Health RITogether provider notice. Coverage continues for type 2 diabetes and other approved uses.

What it means if you pay cash: Affected members must pay cash, through a manufacturer program or a telehealth program, or stop treatment.

Source: Point32Health provider notice · Last verified November 20, 2026

CMS: the Medicare GLP-1 Bridge runs through December 31, 2027

· confirmed (agency page)

The CMS BALANCE model page, last modified September 29, 2026, says the Medicare GLP-1 Bridge has been extended through December 31, 2027 and answers an FAQ about "the BALANCE Model not launching in Medicare in 2027". Per Medicare.gov, the Bridge covers Foundayo, Wegovy and the Zepbound KwikPen only, for eligible people at a $50 copay; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.

What it means if you pay cash: Eligible Medicare enrollees pay $50 a month for those brand drugs through 2027 instead of paying cash.

Source: CMS BALANCE model

Two charged over counterfeit Ozempic sourced from China

· confirmed (agency page)

FDA announced that federal prosecutors in the Middle District of Florida charged two Indian nationals with conspiracy and smuggling, alleging they distributed counterfeit Ozempic between July 2023 and April 2024. An indictment is an allegation only.

What it means if you pay cash: Buy brand GLP-1s only through licensed pharmacies or the manufacturers' own programs.

Source: FDA press announcement

FDA warning letter 738238 to Empower Pharmacy

· confirmed (agency page)

FDA's warning letter to Empower Pharmacy, dated September 18, 2026 and posted September 22, says its compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites insanitary conditions. Empower had 15 working days to respond.

What it means if you pay cash: If your program uses a 503A pharmacy, ask which one and whether it has open FDA actions.

Source: FDA warning letter 738238

Explainers

  • Proposed April 30, 2026 · comment period closed July 30, 2026

    FDA moves to exclude GLP-1s from the 503B bulks list

    The agency proposed finding no clinical need for bulk compounding of semaglutide, tirzepatide, and liraglutide at outsourcing facilities — the single decision with the most leverage over the compounded-GLP-1 market.

  • Seizures April 2025 and December 2025

    Counterfeit Ozempic reached licensed U.S. pharmacies twice

    Both confirmed counterfeit incidents involved product inside the legitimate supply chain — with authentic lot numbers — which changes what "buy from a licensed pharmacy" can and cannot protect against.

  • Warning-letter rounds September 2025 – June 2026, as reported

    FDA's enforcement wave against compounded GLP-1 marketing

    Over a hundred warning letters to telehealth companies and online sellers in three reported rounds, plus an announced move against compounded GLP-1 ingredients — much of it reaching us through trade press, and labeled accordingly.

How these explainers work

We separate event reporting from analysis. Every dated fact cites an evidence-ledger record whose source you can open; claims we could only source to trade press are markedthird-party reported in the text, not silently blended with agency records. Where a development's outcome is not yet public — a pending decision, an unpublished docket result — the page says "unknown" rather than predicting.

Frequently asked questions

What did the FDA do about compounded GLP-1s in 2026?

In 2026 the FDA proposed on April 30 not to place semaglutide, tirzepatide or liraglutide on the 503B bulks list, sent warning letters to telehealth sellers in February, June and October and to Empower Pharmacy on September 18, and updated its page on unapproved GLP-1 drugs on October 1. No final 503B decision was found as of November 20, 2026. Four compounded GLP-1 recalls were classified this fall. For a patient, the practical question is which pharmacy fills your prescription and whether its name appears on a recall list.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Cite this page

GLP Ranked. "GLP-1 news ledger: 17 developments to November 20, 2026." https://glpranked.com/news/

GLP Ranked. "GLP-1 news ledger: 17 developments to November 20, 2026." https://glpranked.com/news/